INTRODUCTION
============

The human genome contains several types of structural variations that contribute to genetic diversity and disease susceptibility [@b1-cln_72p526],[@b2-cln_72p526]. These structural variations include single nucleotide alterations, such as point mutations or SNPs (single nucleotide polymorphisms), small InDels, and copy number variations (CNVs) [@b1-cln_72p526],[@b3-cln_72p526].

CNVs are the most prevalent type of structural variation in the human genome and can affect the transcription rate, sequence, structure, and function of genes. These genomic variations include a range of deletions and duplications larger than 1 kb and up to several Mb [@b1-cln_72p526],[@b2-cln_72p526].

Although these variations often represent only small genomic segments, they can generate several specific clinical abnormalities, such as developmental delay (DD) and multiple congenital abnormalities (MCAs) [@b1-cln_72p526]-[@b4-cln_72p526]. However, the etiology of these disorders is not well understood, making genetic counseling and treatment difficult [@b1-cln_72p526],[@b2-cln_72p526],[@b5-cln_72p526].

Different cytogenomic techniques have been used to detect these changes, including the MLPA (multiplex ligation-dependent probe amplification) and array techniques [@b1-cln_72p526],[@b6-cln_72p526],[@b7-cln_72p526].

MLPA is a technique that is used to detect deletions and duplications in genetic diseases of interest, such as the most common microdeletion/microduplication syndromes and subtelomeric regions [@b8-cln_72p526],[@b9-cln_72p526].

This method is considered a faster alternative and is more economically viable than other molecular techniques [@b3-cln_72p526],[@b10-cln_72p526], and it allows quantitative genomic screening of target-specific sequences through simultaneous hybridization and amplification via polymerase chain reaction (PCR) using more than 50 different probes in a single reaction [@b3-cln_72p526],[@b8-cln_72p526],[@b11-cln_72p526],[@b12-cln_72p526].

The screening of specific submicroscopic changes via MLPA detects abnormalities in 5 to 10% of patients with a normal conventional karyotype [@b13-cln_72p526]-[@b15-cln_72p526]. Thus, in a single test, the MLPA evaluates patients with characteristics of microdeletion/microduplication syndromes and/or patients with suspected subtelomeric abnormalities [@b9-cln_72p526],[@b15-cln_72p526]-[@b18-cln_72p526].

Although MLPA allows the evaluation of multiple different genomic regions, the main limitation of this technique is the need for a clinical hypothesis to direct the selection of a specific kit for analysis [@b3-cln_72p526],[@b8-cln_72p526]. In contrast, the array technique does not require a specific clinical diagnosis before use.

The array technique permits the assessment of the CNVs present in the whole genome of a patient in a single reaction with a high level of resolution (∼0.7 kb), depending on the platform, types of probes and how they are distributed in the genome, thus increasing the detection rate of complex imbalances [@b4-cln_72p526],[@b19-cln_72p526],[@b20-cln_72p526].

This technique involves the hybridization of probes to complementary DNA (genomic sequence segments) on a slide or chip array and subsequent analysis of the fluorescence annealed to the target DNA sequences using specific software [@b7-cln_72p526],[@b21-cln_72p526].

Currently, there are several companies that offer this technology on different platforms, offering slides or chips with a high density or coverage of the genome. However, these platforms vary in the number of probes used, and several of them can interrogate millions of regions in a single sample [@b4-cln_72p526],[@b7-cln_72p526],[@b20-cln_72p526],[@b22-cln_72p526],[@b23-cln_72p526].

The main advantage of the array technique is the ability to investigate the entire genome in a single experiment with higher resolution and accuracy compared with traditional and molecular cytogenetics, as this allows the investigation of small changes that may have an impact on the phenotype of patients without a definitive clinical diagnosis [@b19-cln_72p526],[@b22-cln_72p526],[@b24-cln_72p526].

Thus, arrays have been employed to diagnose patients with DD and MCAs as well as normal karyotypes, increasing the detection rate of small genomic imbalances and the diagnosis of patients with clinical phenotypes of unknown etiology [@b22-cln_72p526],[@b25-cln_72p526].

The main limitations of the array technique are the high cost of large-scale application for developing countries, the experimental time required (3-5 days), and the expertise required for classification of the results (CNVs), which can only be interpreted by a highly qualified professional [@b25-cln_72p526]-[@b27-cln_72p526].

An unequivocal diagnosis is fundamental to providing suitable answers regarding the prognosis and risk of recurrence and can contribute to improving public health policy [@b2-cln_72p526],[@b25-cln_72p526],[@b28-cln_72p526].

In developed countries, the array technique is already being used as the first-line molecular diagnostic test in patients with MCA [@b28-cln_72p526],[@b29-cln_72p526]. Recently, Brazil has modified its policies in the field of genetics, including the clinical genetics policy guidelines of the *Sistema Único de Saúde* (SUS), and has provided financial incentives to cover the costs of genetic testing and counseling in the national health network (<http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_atencao_integral_pessoa_doencas_raras_SUS.pdf>).

Thus, genetic services must study the best strategies for molecular assessment to diagnose each patient referred with DD and MCA, as the introduction of a single molecular diagnostic method, such as array technology, as a first-line assessment method for patients with DD and MCA is impractical in Brazil due to insufficient public investment in the health care system and because low-income patients cannot afford such tests.

In this study, we report our experience with the implementation and assessment of MLPA using different kits, array platforms (Affymetrix, Agilent and Illumina), and probe densities for the molecular diagnostic and scientific analysis of 93 Brazilian patients with DD and MCA.

MATERIALS AND METHODS
=====================

This study involved 93 patients who were evaluated using MLPA and array techniques. The patients presented with DD and MCAs, such as minor facial anomalies, including a high forehead, frontal bossing, broad nasal bridge, low-set ears, ocular hypertelorism, and abnormalities of the eyes, as well as major congenital defects, such as skeletal and genital malformations, heart defects, and structural brain abnormalities.

All patients were previously assessed through conventional cytogenetic analysis to identify their numerical and structural chromosomal abnormalities; metaphase chromosomes were obtained from peripheral blood lymphocyte samples the patients, and G-banding analysis was performed using standard procedures. In each case, twenty metaphase chromosomes were analyzed at a 550-chromosome band resolution (≥5 Mb) and then classified according to the International System for Human Cytogenetic Nomenclature 2013 (ISCN) guidelines.

Genomic DNA was isolated from 3 mL of peripheral whole blood from patients using a commercially available DNA isolation kit (QIAamp DNA Blood Mini Kit^®^, Qiagen, Hilden, Germany) according to the manufacturer's instructions. The quality and quantity of the DNA samples were determined using a Qubit^®^ 2.0 Fluorometer (Invitrogen, Carlsbad, California, USA), and the integrity of the DNA was ascertained via agarose gel electrophoresis analysis.

All of the genomic DNAs were screened with the following three MLPA kits: for the most common microdeletion/microduplication syndromes, the SALSA MLPA probemix P064-B2 Mental Retardation-1 kit was employed, which includes probes for the 1p36 deletion, Williams-Beuren, Smith-Magenis, Miller-Dieker, 22q11.2 deletion, Prader-Willi/Angelman, Alagille, Saethre-Chotzen, and Sotos syndromes; for subtelomeric imbalances, the SALSA MLPA probemix P036-E1 Human Telomere-3 and SALSA MLPA probemix P070-B2 Human Telomere-5 kits were used, which include subtelomeric probes for all chromosomes (MRC-Holland, Amsterdam, Netherlands).

In several cases, the patients' genomic DNA samples were also assessed using specific MLPA kits to confirm the observed changes. The kits used in these cases were the SALSA MLPA probemix P250-B1 DiGeorge and SALSA MLPA probemix P356-A1 Chromosome 22q kits, which are specific for chromosome 22, and the SALSA MLPA probemix P029-A1 Williams-Beuren Syndrome kit, which is specific for changes in chromosome 7q11 (MRC-Holland, Amsterdam, Netherlands).

DNA denaturation, hybridization of probes, ligation, and PCR were performed according to the manufacturer's instructions, as described by Schouten et al. [@b11-cln_72p526]. Separation of the amplification products via electrophoresis was performed using an ABI 3500 Genetic Analyzer (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and the data were analyzed using GeneMarker software, version 1.6 (www.softgenetics.com-Softgenetics, State College, Pennsylvania, USA).

The peak area of each fragment was compared with that of a control sample, and the results were considered abnormal when the relative peak-height ratio was less than 0.75 (deletion) or greater than 1.25 (duplication). The details of the regions and probes detected by each kit can be found at [www.mlpa.com](www.mlpa.com).

The arrays were employed on three different platforms, from Agilent Technologies (Santa Clara, California, USA), Affymetrix (Santa Clara, California, USA) and Illumina (San Diego, California, USA), which differ in the technology used.

On the Agilent platform, we used the Human Genome CGH Microarray 2x105K slide, containing 105,750 probes with an average spacing of 22 kb, the SurePrint G3 Human CGH Microarray 4x180K slide, containing 180,880 probes distributed throughout the genome with an average spacing of 13 kb, and the SurePrint G3 Human CGH Microarray 8x60K slide, containing 62,976 probes with an average spacing of 41 kb.

On the Affymetrix platform, we used the Affymetrix Genome-Wide Human SNP Array 6.0 chip (1.8 million genetic markers), which contains 906,600 single-nucleotide polymorphism (SNP) probes and over 946,000 probes for the detection of CNVs, with a median physical inter-marker distance of 1-5 kb, as well as the CytoScan HD chip, which contains 2,696,550 CNV probes and 749,157 SNP probes, with an average spacing of 1.1 kb.

On the Illumina platform, we employed the HumanCytoSNP-12 BeadChip, with 300,000 oligonucleotide probes and an average spacing of 9.7 kb, and the CytoSNP-850K, with 843,888 markers and an average probe spacing of 1.8 kb across the whole array.

In all samples, amplification, hybridization, staining and washing were performed according to the manufacturers' protocols, and the data were extracted by a specific scanner. The CGH arrays are based on the principle of comparison between the signal intensities of a sample and commercially acquired human male control DNA (Promega Corporation, Madison, Wisconsin, USA). For the SNP arrays (Affymetrix) and bead arrays (Illumina), only a single hybridization is performed for the patient DNA, and the signal intensities are then compared with a reference dataset based on pre-run reference samples.

The raw data were analyzed using Feature Extraction v9.5, Affymetrix Chromosome Analysis Suite (ChAS) v.1.2, or KaryoStudio v1.4.3.0 Build 37 software. The data were normalized, and log~2~ ratios were calculated by dividing the normalized intensity of the sample by the mean intensity across the reference sample.

The criteria used to determine a CNV included the involvement of at least five consecutive probes sets in a region and log2 ratio cut-offs of -0.41 and +0.32 for loss and gain, respectively. The software produced graphical representations of CNV breakpoints for each sample.

The SNP and bead arrays supply the B allele frequency (BAF), which represents the proportion of B alleles in the genotype. A region without evidence of CNVs should show a log~2~ ratio near zero and three BAF clusters of 0, 0.5, and 1, corresponding to the AA, AB, and BB genotypes, respectively.

All samples were evaluated and were found to be in accordance with the quality standards.

The results were analyzed according to the American College of Medical Genetics guidelines [@b30-cln_72p526] using independent tests and were compared with the following databanks of CNVs and classified as benign, pathogenic or VOUS (variants of uncertain clinical significance): the Database of Genomic Variants (DGV -- <http://projects.tcag.ca/variation/>), the Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources (DECIPHER -- <http://decipher.sanger.ac.uk/>) and the UCSC Genome Bioinformatics database (<http://genome.ucsc.edu>). The genomic positions are reported according to their mapping on the GRCh37/hg19 genome build.

Ethics
------

The Research Ethics Committee of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP) approved this study, and written informed consent for publication was obtained from the parents of the patients (CAPPesq n° 0619/11).

RESULTS
=======

In this study, we assessed 93 patients with DD and MCAs via the MLPA and array techniques. The patients showed either a normal karyotype or a karyotype with an undetermined abnormality according to G-banding, which made it impossible to obtain a conclusive diagnosis.

We found that ∼97.8% (91/93) of the results from the two methods were consistent with each other (all results are described in [Table 1](#t1-cln_72p526){ref-type="table"}). Among the evaluated patients, ∼13.2% (12/91) showed no alterations according to either technique; ∼54.9% (50/91) only showed changes in the array analysis; and ∼39.9% (29/91) of the patients showed CNVs according to both techniques ([Figure 1](#f1-cln_72p526){ref-type="fig"}).

One case with inconclusive results was found in our cohort, and further evaluation using other molecular techniques should be performed to definitively diagnose this patient. Although the changes observed using both techniques were consistent, the breakpoint determined by the array did not correspond exactly to the genomic localization of the MLPA probe, and there were several array probes between these two probes.

The MLPA results were inconsistent with the array results in two cases. We found a duplication in the *FZD9* gene in one case (P064 and P029), and in the other, we identified two alterations (del 16p13.3 with the P036 kit and del 19p13.3 with the P070 kit) using MLPA, which were confirmed via independent reactions. However, these alterations were not identified with the array because none of the array probes are located at exactly the same position as the MLPA probe.

Several of the MLPA results were inconclusive, but this did not affect the comparison of the techniques because the regions targeted by MLPA were repeated in several of the kits used in this study. Thus, the results were concordant, and although the results were not the same in all cases, the MLPA technique detected ∼70.6% of the pathogenic CNVs detected using the array.

MLPA Analysis
-------------

The MLPA technique was employed to diagnose all patients using several different kits. No changes were detected in ∼66.7% (62/93) of the patients, and in four cases, one or two kits showed inconclusive results; however, these cases did not influence the assessment and interpretation of the results.

CNVs were detected with at least one of the kits in ∼33.3% (31/93) of patients ([Figure 2](#f2-cln_72p526){ref-type="fig"}). Approximately 22.6% (7/31) of these changes were detected by the P064 kit, corresponding to one deletion typical of the Williams-Beuren syndrome, one duplication in chromosome 7q11, and five deletions of 22q11.2, which were atypical in three patients and typical in the other two patients. All alterations were confirmed by the specific P029, P250 and/or P356 kits.

We also detected subtelomeric alterations in ∼45.2% (14/31) of the patients. One deletion was detected in two patients; two duplications in different chromosomes were detected in one patient; two deletions were found in another patient, one of which was detected with the P036 kit and the other with the P070 kit; and the remaining 10 patients showed concomitant deletions and duplications, all of which were present in the subtelomeric regions of different chromosomes.

The MLPA test also allowed us to simultaneously detect CNVs with all of the main kits used in this study (P064, P036 and P070); these changes were identified in ∼25.8% (8/31) of the patients.

One atypical duplication (in the *PRODH* gene) was only detected by the P356 kit, specific for chromosome 22, and one deletion in chromosome 8p23 (three probes) was detected with the P250 kit.

ARRAY Analysis
--------------

The array technique was applied to all patients using different platforms (Agilent, Affymetrix or Illumina) and chip densities. The results showed that ∼14% (13/93) of the patients did not exhibit CNVs, while ∼86% (80/93) exhibited several different genomic alterations, including deletions, duplications and loss of heterozygosity (LOH). These changes were classified as pathogenic, benign or VOUS.

Among the patients showing changes in the genome, we observed a 46.25% (37/80) detection rate for patients with benign and/or VOUS CNVs and a 53.75% (43/80) rate for patients with at least one pathogenic change ([Figure 3](#f3-cln_72p526){ref-type="fig"}).

Among the patients with pathogenic CNVs, ∼51.2% (22/43) exhibited only one alteration that was considered pathogenic, while ∼44.2% (19/43) showed at least two changes with important clinical significance, and ∼4.6% (2/43) of patients exhibited three or more pathogenic CNVs, possibly due to complex rearrangements. In several cases, these patients with pathogenic changes also displayed concomitant benign changes or VOUS.

Regarding the size of the changes, the majority of patients exhibited benign CNVs or VOUS ranging from 100 to 500 kb and pathogenic CNVs that were larger than 1 Mb.

DISCUSSION
==========

Establishing an unequivocal clinical and molecular diagnosis for patients with DD and MCA is essential for correlating genotypes and phenotypes and making genetic counseling more effective.

With advances in cytogenomic techniques, different syndromes can be better evaluated. Thus, for certain changes, specific genes are now highlighted as being responsible for most of the clinical features of a defined syndrome, whereas for others it is possible to determine alterations in an increasing number of critical regions associated with specific clinical characteristics [@b1-cln_72p526],[@b6-cln_72p526].

Currently, the MLPA technique has become very useful for the detection of the main microdeletion/microduplication syndromes and subtelomeric imbalances, as it is a rapid technique that is able to detect typical changes correlated with specific phenotypes (e.g., Williams-Beuren syndrome or deletion of 22q11.2), in addition to being detecting small and/or atypical deletions and duplications in target regions [@b9-cln_72p526],[@b15-cln_72p526],[@b16-cln_72p526]. MLPA has the ability to assess more than 45 target regions in a single reaction without cell culture, making it a cost-effective and widely used technique for the validation of other methods, such as array-based analysis [@b12-cln_72p526],[@b15-cln_72p526].

In this study, MLPA analysis using the P064 and/or P036 and P070 kits detected alterations in approximately 33.3% of patients. Using the same combination of MLPA kits, Jehee et al. [@b31-cln_72p526] identified pathogenic changes in 21.8% of 261 patients with DD and MCA.

In a study performed on 258 patients with intellectual disabilities and dysmorphisms in 2007, the rate of the detection of alterations using several kits was 10.1%, among which only 5.8% were changes in regions correlated with syndromes, and 5.0% were associated with subtelomeric regions [@b15-cln_72p526].

In the patients included in the present study, the changes identified with a specific kit for the main microdeletion/microduplication syndromes (P064) corresponded to ∼7.5% of all samples, or ∼22.6% of all changes, representing Williams-Beuren syndrome, duplications of chromosome 7q11 and deletions of chromosome 22q11.2. In addition, subtelomeric changes were found in ∼15.1% of the samples evaluated via MLPA, or ∼45.2% of the patients with copy number changes. In a similar study, the detection rate for alterations in the regions of the main microdeletion/microduplication syndromes was 6.6%, and the detection rate for subtelomeric alterations was 7.3% [@b10-cln_72p526].

The percentage of copy number changes detected in the genome via MLPA depends on the criteria used to select patients, and the data obtained in this study corroborate the data reported in the literature for the regions corresponding to the main syndromes. However, the obtained values for subtelomeric regions were higher than those previously described by several authors.

A subtelomeric analysis conducted by Koolen et al. [@b14-cln_72p526] detected changes in 6.7% of 210 patients with idiopathic intellectual disabilities. Two years later, Palomares et al. [@b32-cln_72p526] detected alterations in 10% of patients with the same phenotypic characteristics using subtelomeric kits.

With the exception of two cases, all of the patients who presented only subtelomeric abnormalities exhibited two changes: one deletion associated with one duplication on different chromosomes, or two deletions or duplications. This set of changes in the same patients may result from complex rearrangements and translocations between chromosomes or regions of instability that are susceptible to rearrangements via DNA repair mechanisms.

We also detected changes with the three main kits used in this study (P064, P036 and P070) accounting for ∼25.8% of the CNVs identified among the abnormal results. These alterations may result from a microdeletion syndrome located near the telomere of a chromosome, such as 1p36 deletion syndrome, or complex rearrangements between different regions of chromosomes due to instability and microhomology.

In addition to the changes detected by the main kits used in this study, we were able to identify an atypical change involving a single gene (2 exons evaluated) using the P356 kit and a deletion in 8p23 (3 genes evaluated) using the P250 kit. These alterations are rare and difficult to detect because they involve specific genes or exons that are associated with few clinical characteristics, or a phenotype present in most patients, making it difficult to determine the correct kit to use.

An important limitation of MLPA is that the signal intensity of the probes varies according to DNA characteristics, including those associated with the extraction method, storage time, elution solution, degree of degradation (if present), and the presence of several types of contaminants, such as extraction reagents, proteins, RNAs, and salts. These influences can be minimized if all samples are prepared by the same technician using the same method. However, it is not always possible to eliminate this bias because samples may be sent from other locations, and storage times and DNA extraction methods may differ from the standard, which can cause artifacts during analysis that only a specialist can identify [@b8-cln_72p526],[@b18-cln_72p526].

In our analyses using the MLPA technique, 4 patients showed inconclusive results with one or two of the kits, but none of these findings limited the detection of changes because the surveyed regions were represented in the other kits used in this study. These data highlight the importance of using different combinations of kits because one kit can act as a control for another, confirming the alterations detected and excluding false positive and negative results [@b10-cln_72p526],[@b32-cln_72p526].

In a study performed by Marenne et al. [@b2-cln_72p526], MLPA was used to validate data from arrays. DNA from 56 patients were analyzed via MLPA in two independent reactions, providing a concordance rate of 97.25%. Therefore, MLPA is a reproducible technique.

The sizes and breakpoints of chromosomal abnormalities can currently be determined with greater precision, accuracy and sensitivity using array techniques [@b6-cln_72p526],[@b19-cln_72p526].

All of the patients included in our study were assessed using the array technique according to the availability of platforms or slides/chips in the laboratory (Agilent, Affymetrix or Illumina). The slides/chips differ in the technologies involved (CGH, oligonucleotides or beads) and in the number and spacing of probes distributed throughout the genome. Technologies with higher genome coverage provide more accurate breakpoint data and can be used to diagnose micro changes or several CNVs that were previously considered a single alteration (e.g., a normal region interposed by two affected regions). In these cases, the low coverage of several arrays may determine those changes to be a single deletion and not a complex rearrangement that may reflect a change in the patient's phenotype [@b4-cln_72p526],[@b19-cln_72p526],[@b33-cln_72p526].

A total of 93 samples were evaluated, and all of the different technologies employed proved to be satisfactory for detecting variations in the genome, which in most cases corroborated the clinical characteristics of each patient.

The data included results that were considered normal (without changes) for ∼14% of the patients. This rate is much lower than that described in the literature. In 2013, Vallespín et al. [@b27-cln_72p526] evaluated 540 samples (patients with learning disabilities, autism and/or multiple congenital malformations) using a customized array with an average coverage of ∼43 kb and showed that no CNVs were detectable in 31.85% of the patients. In this study, the samples that were considered normal were assessed using Agilent 180K (2/13 patients), Agilent 60K (1/13 patients) and Illumina (10/13 patients) arrays, all of which exhibit a high rate of genome coverage. The results (particularly those from the Illumina platform; 65 samples), were considered normal because the majority of the evaluated patients had not received a suspected clinical diagnosis. These patients should be further evaluated and subjected to exome sequencing or targeted tests searching for mutations in specific genes or gene disruptions due to unbalanced translocations [@b4-cln_72p526],[@b20-cln_72p526].

Among the patients who presented alterations in the genome, the array technique showed that 46.25% of the patients presented benign changes or changes of uncertain clinical significance, while 53.75% of the patients presented at least one pathogenic change.

Among the patients exhibiting alterations of clinical significance, the majority of patients presented only one or two pathogenic changes in the genome, which were or were not combined with other alterations, corresponding to ∼51.2% and ∼44.2% of the patients, respectively. Complex alterations with three or more pathogenic CNVs in different regions were observed in approximately 4.6% of the patients.

The detection rate of pathogenic alterations visualized in this study was much higher than the rates previously reported in several articles. Rosenberg et al. [@b34-cln_72p526] investigated 81 patients with intellectual disabilities and facial dysmorphisms via the CGH array technique and concluded that 16% of the patients exhibited a pathogenic chromosomal imbalance related to their phenotype, while 4% of the patients exhibited changes of uncertain clinical significance. Gijsbers et al. [@b25-cln_72p526] used several SNP array platforms to investigate patients with intellectual disabilities and multiple congenital abnormalities and detected alterations in 22.6% of 318 evaluated patients. Therefore, array analysis was considered the most appropriate test for the initial molecular investigation of patients with these characteristics and normal karyotypes.

Hochstenbach et al. [@b28-cln_72p526] also recommended arrays as the first diagnostic test in this patient group. Based on analyzing many studies, they concluded that the rate of detection using arrays would correspond to at least 19% of pathogenic changes. Other studies have shown similar rates, regardless of the platform selected to diagnose patients with intellectual disabilities, malformations and/or neurological disorders and normal karyotypes [@b20-cln_72p526],[@b27-cln_72p526],[@b28-cln_72p526].

Regarding the size of the observed changes, we identified the greatest number of patients with pathogenic CNVs that were larger than 1 Mb. These large changes usually involve more causative genes of a disease. However, the severity of the clinical manifestations in patients is not necessarily directly correlated with the size of the change but is correlated with location and gene content. Therefore, a small change can potentially reflect a more severe phenotype due to the pathogenicity of the altered gene [@b1-cln_72p526],[@b35-cln_72p526].

With the implementation of SNP arrays, it has become possible to identify changes that were previously undiagnosed using CGH arrays. In this study, we identified four patients with LOH or UPD regions that can be correlated with recessive disorders [@b20-cln_72p526],[@b24-cln_72p526],[@b25-cln_72p526].

The main challenge in analyzing the results of the arrays is determining which changes are significant for each patient, as it is common to identify more than one change per patient, and all of the changes could potentially influence the phenotype in many cases. The identification of benign and VOUS changes is associated with the increased array density used for diagnosis, as arrays with a greater number of probes are able to identify a greater number of microalterations and determine the breakpoints of these changes with higher accuracy. However, the identification of regions involving genes without an established function or regions that do not contain well-described genes will also increase [@b24-cln_72p526],[@b27-cln_72p526],[@b29-cln_72p526].

All of the changes detected in the present study were checked against several international databases, including the DGV, Decipher and UCSC databases. Nevertheless, a more appropriate assessment of the changes identified in our patients would result in the creation of a database with information specifically from Brazilian people.

Most of the obtained results (∼97.8%) were concordant with each other for the regions investigated. However, not all of the results were in agreement, as the MLPA technique covers approximately 45 specific regions of the genome in each available kit, and this technique therefore depends on a clinical features and direction toward a specific target. Approximately 54.9% of the CNVs were not detected via MLPA compared with array analysis, and higher rates for this comparison (72-81%) are reported in the literature [@b2-cln_72p526].

Despite the presence of the same alteration, one case was discordant in relation to the breakpoints detected via array analysis and the position of the MLPA probe. Therefore, to obtain a conclusive molecular diagnosis, other techniques should be applied to reevaluate the exact breakpoints involved.

All of the techniques employed in this study have advantages and disadvantages depending on the application and could potentially be applied together to obtain a complete molecular diagnosis.

Our findings showed that the interpretation of genotype-phenotype correlations in patients with complex genomic rearrangements is very difficult, but these results can directly contribute to the elucidation of new syndromes.

Arrays are a powerful tool for the identification and characterization of genomic abnormalities and can provide accurate diagnoses of previously unidentified or unexplained diseases that are suspected to have a genetic cause, contributing to appropriate clinical management of the affected patients. When an array is not available, MLPA with a combination of three kits (P064, P036 and P070) is a remarkable tool that can detect abnormalities in patients with DD and MCA [@b10-cln_72p526],[@b15-cln_72p526],[@b31-cln_72p526].

Clinical and laboratory interactions with skilled technicians are required to target a patient for the most effective and beneficial molecular diagnosis, in which an appropriate clinical hypothesis is crucial for the successful detection of changes.

Patients exhibiting normal results or benign alterations may present a clinical phenotype due to balanced rearrangements with disruptions in several genes or mutations in specific genes. In this case, other molecular techniques are required to achieve a complete diagnosis, such as exome sequencing, which can detect changes in 80% of patients with developmental delays of unknown cause, and analysis using normal arrays [@b4-cln_72p526],[@b20-cln_72p526].
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![Cytogenomic map of the raw data of all alterations identified via the MLPA and array techniques. The gray circles represent the locations of the breakpoints of the alterations identified by both techniques, in which the center circle corresponds to the MLPA results and the middle circle to the array results. Each bar refers to the position of each identified copy number change: the red bar refers to deletions, the blue to duplications, and the green to loss of heterozygosity. The genomic positions are reported according to their mapping on the GRCh38/hg38 genome build from the UCSC Genome Browser.](cln-72-09-526-g001){#f1-cln_72p526}

![The results of MLPA. The blue bar indicates the number of duplications; the red bar indicates deletions; and the green bar indicates the number of normal results detected via MLPA.](cln-72-09-526-g002){#f2-cln_72p526}

![The number of CNVs identified on each chromosome via the array technique. The red bar indicates pathogenic CNVs; the blue bar indicates benign CNVs; the gray bar indicates VOUS; and the green bar indicates LOH.](cln-72-09-526-g003){#f3-cln_72p526}

###### 

Description of cytogenomic results obtained via the MLPA and array techniques.

  ID                    Array results               MLPA results                                                                                                                                                                                                                                               
  --------------------- --------------------------- --------------------------- ------------------- ------------ -------------------------------------------- ------------------------------- ------------------------------- ---------------------------------------------- --------------------------------- -------------------------------------------------------
  01                    del 17p11.2                 17,626,111 - 17,640,000     13,889              Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  02                    del 19p13.12                14,729,069 - 14,768,462     39,393              Benign       nml                                          nml                             nml                             \-                                             \-                                nml
  03                    del 22q11.21                21,034,808 - 21,572,202     537,394             VOUS         del 22q11.21 atypical (*SNAP29*)             nml                             nml                             del 22q11.21 atypical (*SNAP29* and *LZTR1*)   nml                               \-
  04                    dup 7q11.23→q22.1           74,480,670 - 99,700,362     25,219,692          Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  05                    dup 22q11.21                18,844,632 - 18,979,405     134,773             VOUS         nml                                          nml                             nml                             nml                                            inconclusive                      \-
  06                    dup 18q22.2→q22.3           68,090,674 - 68,756,043     665,369             VOUS         nml                                          nml                             nml                             nml                                            \-                                \-
  07                    dup 17q21.31                44,204,373 - 44,788,310     583,937             Pathogenic   nml                                          nml                             nml                             nml                                            dup 22q11.21 atypical (*PRODH*)   \-
                        dup 22q11.21                18,877,787 - 19,008,108     130,321             VOUS                                                                                                                                                                                                       
  08                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  09                    dup Xq22.2                  103,111,457 - 103,303,968   192,511             VOUS         nml                                          nml                             nml                             \-                                             \-                                \-
  10                    del 1q21.1→q21.2            146,516,199 - 147,828,939   1,312,740           Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  11                    dup 12q13.11                47,608,167 - 47,740,591     132,424             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  12                    del 8p23.2                  4,814,896 - 5,044,296       229,400             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  13                    del 16p11.2                 32,502,868 - 32,951,981     449,113             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  14                    del 6q25.2→q27              153,258,023 - 165,115,007   11,856,984          Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  dup Xp22.33           1,957,876 - 2,065,015       107,139                     Benign                                                                                                                                                                                                                         
  15                    dup 22q13.31                47,327,892 - 47,675,283     347,391             Benign       nml                                          nml                             nml                             inconclusive                                   nml                               \-
  16                    dup 22q11.22                22,314,463 - 22,580,314     265,851             Benign       nml                                          nml                             nml                             inconclusive                                   nml                               \-
  17                    del 22q11.21                18,877,787 - 21,462,353     2,584,566           Pathogenic   del 22q11.21 typical                         nml                             nml                             del 22q11.21 typical                           del 22q11.21 typical              \-
  dup Xq28              152,667,088 - 153,878,001   1,210,913                                                                                                                                                                                                                                                  
  18                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  19                                                No change                                                    dup 7q11.23 atypical (*FZD9*)                nml                             nml                             \-                                             \-                                dup 7q11.23 atypical (*FZD9*)
  20                    del 6q24.3→q25.1            148,971,363 - 149,820,948   849,585             VOUS         nml                                          nml                             nml                             \-                                             \-                                nml
  21                    del 17q23.3                 61,947,000 - 61,977,500     30,500              Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  del Xq22.1            99,904,100 - 99,905,800     1,700                                                                                                                                                                                                                                                      
  22                    del 4q34.3→q35.2            179,962,284 - 190,790,881   10,828,597          Pathogenic   dup 5q35.3 typical                           dup 5q35.3; del 4q35.2          dup 5q35.3; del 4q35.2          \-                                             \-                                \-
  dup 5q34→q35.3        160,148,716 - 180,712,253   20,563,537                                                                                                                                                                                                                                                 
  23                    dup 12q24.32→q24.33         126,850,508 - 133,819,092   6,968,584           Pathogenic   dup 15q11.12 typical                         dup 12q24.33; dup 15q11.2-cen   dup 12q24.33; dup 15q11.2-cen   \-                                             \-                                \-
  dup 15q11.1→q21.2     20,375,156 - 52,129,171     31,754,015                                                                                                                                                                                                                                                 
  24                    del 9p24.3→p24.2            199,953 - 4,366,197         4,166,244           Pathogenic   nml                                          del 9p24.3; dup 18q23           del 9p24.3; dup 18q23           inconclusive                                   nml                               \-
  dup 18q12.3→q23       39,129,720 - 78,012,829     38,883,109                                                                                                                                                                                                                                                 
  25                    dup 5p15.33→p13.3           37,692 - 33,434,546         33,396,854          Pathogenic   nml                                          dup 5p15.33; dup 14q11.2-cen    dup 5p15.33; dup 14q11.2-cen    \-                                             \-                                \-
  dup 14q11.2→q12       19,361,358 - 25,127,451     5,766,093                                                                                                                                                                                                                                                  
  26                    dup 8p23.2                  2,310,313 - 2,581,969       271,656             Benign       nml                                          nml                             nml                             nml                                            \-                                \-
  27                    dup 9p13.1→p12              40,294,324 - 42,374,011     2,079,687           Pathogenic   nml                                          inconclusive                    nml                             nml                                            \-                                \-
  dup 11q24.2           126,501,321 - 126,671,287   169,966                     VOUS                                                                                                                                                                                                                           
  28                    del 4p16.3→p16.1            48,283 - 6,471,246          6,423,143           Pathogenic   nml                                          del 4p16.3                      del 4p16.3                      nml                                            \-                                \-
  dup 16p13.11          15,052,746 - 16,289,532     1,236,786                                                                                                                                                                                                                                                  
  dup 10q11.22          46,947,635 - 47,741,321     793,686                     VOUS                                                                                                                                                                                                                           
  29                    del 16p12.2                 21,599,125 - 21,740,231     141,106             Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  30                    del 7q11.23                 72,722,981 - 74,138,121     1,415,140           Pathogenic   del 7q11.23 typical                          nml                             nml                             \-                                             \-                                \-
  dup Xq24              117,394,974 - 117,742,647   347,673                     VOUS                                                                                                                                                                                                                           
  LOH 4q24-q26          102,641,428 - 118,463,264   15,821,836                  4 regions -- LOH                                                                                                                                                                                                               
  LOH 4q32.3-q34.1      166,848,001 - 175,764,593   8,916,592                                                                                                                                                                                                                                                  
  LOH 17p13.2-p12       6,004,639 - 12,043,573      6,038,934                                                                                                                                                                                                                                                  
  LOH 17q21.2-q22       38,640,744 - 54,902,055     16,261,311                                                                                                                                                                                                                                                 
  31                    del 3p13→p12.1              74,143,047 - 85,618,308     11,475,261          Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  del Xp11.23           47,871,775 - 48,001,226     129,451                     Benign                                                                                                                                                                                                                         
  del 7p21.1→p15.3      20,703,948 - 21,582,516     878,568                     VOUS                                                                                                                                                                                                                           
  32                    del 22q13.2                 41,036,329 - 41,640,297     603,968             Pathogenic   nml                                          nml                             nml                             nml                                            nml                               \-
  33                    del 8q24.23                 137,730,280 - 137,850,011   119,731             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  dup Xp22.33           93,118 - 506,344            413,226                                                                                                                                                                                                                                                    
  34                    del 8p23.2→p23.1            6,143,107 - 6,248,244       105,137             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  dup 10q11.21          45,212,898 - 45,359,483     146,585                                                                                                                                                                                                                                                    
  35                    dup Xp22.31→p22.2           9,353,507 - 9,546,184       192,677             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  dup Xp22.2            11,047,140 - 11,608,207     561,067                                                                                                                                                                                                                                                    
  36                    dup 15q26.3                 100,351,154 - 100,589,056   237,902             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  LOH 3p22.1-p11.1      41,897,482 - 90,442,925     48,545,443                  10 regions -- LOH                                                                                                                                                                                                              
  LOH 3q11.1-q11.2      93,632,889 - 97,474,630     3,841,741                                                                                                                                                                                                                                                  
  LOH 6q21-q25.1        107,328,319 - 149,605,182   42,276,863                                                                                                                                                                                                                                                 
  LOH 6q25.3-q27        156,586,155 - 170,898,549   14,312,394                                                                                                                                                                                                                                                 
  LOH 10q26.12-q26.3    122,697,234 - 131,869,597   9,172,363                                                                                                                                                                                                                                                  
  LOH 13q32.1-q33.1     95,842,069 - 102,302,850    6,460,781                                                                                                                                                                                                                                                  
  LOH 13q33.2-q34       106,386,553 - 115,106,996   8,720,443                                                                                                                                                                                                                                                  
  LOH 16p13.13-p12.1    11,761,688 - 27,853,219     16,091,531                                                                                                                                                                                                                                                 
  LOH 19p13.2-p13.11    8,386,306 - 16,372,158      7,985,852                                                                                                                                                                                                                                                  
  LOH 20p12.2-p12.1     10,082,476 - 15,254,051     5,171,575                                                                                                                                                                                                                                                  
  37                    del 4q32.1→q35.2            161,623,467 - 190,880,409   29,256,942          Pathogenic   nml                                          del 4q35.2                      del 4q35.2                      \-                                             \-                                \-
  dup 5p15.2            13,798,819 - 14,177,667     378,848                                                                                                                                                                                                                                                    
  38                    del 2p11.2                  90,027,810 - 90,247,720     219,910             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  39                    del 2q37.3                  239,550,182 - 243,029,573   3,479,391           Pathogenic   dup 5q35.3 typical                           del 2q37.3; dup 5q35.3          del 2q37.3; dup 5q35.3          \-                                             \-                                \-
  dup 5q35.1→q35.3      172,176,461 - 180,705,539   8,529,078                                                                                                                                                                                                                                                  
  40                    dup 10q11.22                47,087,371 - 47,756,480     669,109             Pathogenic   nml                                          nml                             nml                             nml                                            nml                               \-
  dup 22q13.31          47,330,328 - 47,675,283     344,955                     Benign                                                                                                                                                                                                                         
  41                    del 9p23→p22.3              13,468,616 - 14,566,406     1,097,790           Benign       nml                                          nml                             nml                             nml                                            nml                               \-
  42                    del 7p22.3                  45,130 - 1,691,646          1,646,516           Pathogenic   nml                                          del 7p22.3; dup 12q24.33        del 7p22.3; dup 12q24.33        \-                                             \-                                \-
  dup 12q24.22→q24.33   116,878,379 - 133,819,092   16,940,713                                                                                                                                                                                                                                                 
  43                    dup 5p15.33                 71,904 - 2,425,306          2,353,402           Pathogenic   nml                                          dup 5p15.33; del Yq12           dup 5p15.33; del Yq12           \-                                             \-                                \-
  del Yq11.221→q12      19,571,776 - 59,311,250     39,739,474                                                                                                                                                                                                                                                 
  44                    dup 3q26.31→q29             174,466,591 - 197,845,254   23,378,663          Pathogenic   nml                                          dup 3q29; del 9p24.3            dup 3q29; del 9p24.3            \-                                             \-                                \-
  del 9p24.3→p23        204,104 - 11,659,355        11,455,251                                                                                                                                                                                                                                                 
  45                    del 17p13.3                 148,092 - 2,310,571         2,162,479           Pathogenic   del 17p13.3 atypical (*HIC* and *METTL16*)   del 17p13.3; dup 17q25.3        del 17p13.3; dup 17q25.3        \-                                             \-                                \-
  dup 17q25.1→q25.3     74,307,023 - 80,943,189     6,636,166                                                                                                                                                                                                                                                  
  46                    del 2q33.1                  203,291,000 - 203,312,000   21,000              Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  del 3q28              189,360,000 - 189,364,000   4,000                                                                                                                                                                                                                                                      
  LOH Xq21.1            78,667,293 - 82,400,000     3,732,707                   1 region -- LOH                                                                                                                                                                                                                
  47                    del 1q25.3                  180,300,936 - 180,394,157   93,221              VOUS         nml                                          nml                             nml                             \-                                             \-                                \-
  dup 3q22.1            129,676,581 - 129,896,364   219,783                                                                                                                                                                                                                                                    
  del 9p21.1            32,562,410 - 32,615,311     52,901                                                                                                                                                                                                                                                     
  48                    dup 9p11.2                  41,692,304 - 44,244,868     2,552,564           Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  del 9p11.2            44,727,846 - 44,824,251     96,405                      Benign                                                                                                                                                                                                                         
  dup 9p11.2            44,864,687 - 45,723,022     858,335                     VOUS                                                                                                                                                                                                                           
  49                    del 1p36.33→p36.32          564,620 - 2,456,203         1,891,583           Pathogenic   del 1p36 atypical (*TP73* nml)               del 1p36.33                     del 1p36.33                     \-                                             \-                                \-
  del 1p36.32           2,473,257 - 3,446,813       973,556                                                                                                                                                                                                                                                    
  dup 1p36.32           3,474,630 - 3,641,681       167,051                                                                                                                                                                                                                                                    
  50                    del 8q24.23                 137,730,280 - 137,850,011   119,731             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  dup 7q11.22           71,021,037 - 71,272,257     251,220                                                                                                                                                                                                                                                    
  51                    del 8q24.23                 137,730,280 - 137,850,011   119,731             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  dup 14q11.2           20,213,937 - 20,379,392     165,455                                                                                                                                                                                                                                                    
  LOH 7p15.1-p12.1      28,698,698 - 52,857,194     24,158,496                  8 regions -- LOH                                                                                                                                                                                                               
  LOH 8p23.1-p22        8,105,359 - 18,289,407      10,184,048                                                                                                                                                                                                                                                 
  LOH 8q23.3-q24.23     114,783,837 - 137,679,805   22,895,968                                                                                                                                                                                                                                                 
  LOH 8q24.23-q24.3     137,900,733 - 146,293,086   8,392,353                                                                                                                                                                                                                                                  
  LOH 9q32-q34.11       115,745,240 - 130,633,433   14,888,193                                                                                                                                                                                                                                                 
  LOH 17p13.3-13.1      53,011 - 9,193,945          9,140,934                                                                                                                                                                                                                                                  
  LOH 22q12.3-q13.1     33,850,168 - 40,864,782     7,014,614                                                                                                                                                                                                                                                  
  LOH 22q13.31-q13.33   45,136,360 - 51,169,045     6,032,685                                                                                                                                                                                                                                                  
  52                    dup 4q28.3                  131,880,992 - 132,305,574   424,582             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  del 22q11.23→q12.1    25,732,697 - 25,910,879     178,182                                                                                                                                                                                                                                                    
  dup Xq22.2            103,179,170 - 103,303,968   124,798                     VOUS                                                                                                                                                                                                                           
  53                    del Xp22.13→p22.12          18,179,714 - 19,719,264     1,539,550           Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  54                    dup 14q32.33                106,067,618 -106,823,886    756,268             Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  dup 7q11.23           76,143,705 - 76,615,349     471,644                     Benign                                                                                                                                                                                                                         
  del 5q12.1            59,209,183 - 59,522,613     313,430                     VOUS                                                                                                                                                                                                                           
  55                    del 4q35.1→q35.2            185,821,036 - 190,880,409   5,059,373           Pathogenic   nml                                          del 4q35.2; dup Xq28            del 4q35.2; dup Xq28            \-                                             \-                                \-
                        dup Xq27.1→q28              139,513,770 - 154,929,412   15,415,642                                                                                                                                                                                                                     
                        dup Xp22.33                 2,139,005 - 2,319,653       180,648             Benign                                                                                                                                                                                                     
                        dup Xq28                    154,939,018 - 155,235,833   296,815                                                                                                                                                                                                                        
  56                    dup 9p24→p23                46,587 - 13,014,232         12,967,645          Pathogenic   nml                                          dup 9p24.3; del 18q23           dup 9p24.3; del 18q23           nml                                            nml                               \-
                        del 18q22→q23               70,657,389 - 78,014,582     7,357,193                                                                                                                                                                                                                      
                        dup Xp22.31                 7,811,750 - 8,115,453       303,703             Benign                                                                                                                                                                                                     
  57                    del 2q37.3                  239,550,182 - 243,029,573   3,479,391           Pathogenic   dup 5q35.3 typical                           del 2q37.3; dup 5q35.3          del 2q37.3; dup 5q35.3          \-                                             \-                                \-
                        dup 5q35.1→q35.3            172,246,068 - 180,705,539   8,459,471                                                                                                                                                                                                                      
                        dup 18q12.1                 27,778,530 - 28,050,968     272,438             Benign                                                                                                                                                                                                     
  58                    del 4p16.3→p16.1            48,283 - 9,370,908          9,322,625           Pathogenic   nml                                          del 4p16.3; dup 8p23.3          del 4p16.3; dup 8p23.3          \-                                             \-                                \-
                        dup 8p23.3→p23.1            176,818 - 6,974,050         6,797,232                                                                                                                                                                                                                      
  59                    dup 4q26→q35.2              118,777,687 - 190,880,409   72,102,722          Pathogenic   nml                                          dup 4q35.2; del 7q36.3          dup 4q35.2; del 7q36.3          \-                                             \-                                \-
  dup 6q27              168,329,404 - 168,612,631   283,227                     Benign                                                                                                                                                                                                                         
  del 7p21.2            14,436,385 - 14,737,999     301,614                     VOUS                                                                                                                                                                                                                           
  del 7q36.3            158,498,994 - 159,119,486   620,492                                                                                                                                                                                                                                                    
  60                    dup 6p22.3→p12.3            24,247,896 - 50,203,633     25,955,737          Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  dup 2q22.2→q22.3      143,387,612 - 145,082,658   1,695,046                   VOUS                                                                                                                                                                                                                           
  dup 10q11.22          46,972,140 - 47,681,957     709,817                                                                                                                                                                                                                                                    
  61                    dup 2p25.3→p24.3            72,184 - 14,844,939         14,772,755          Pathogenic   nml                                          inconclusive                    dup 2p25.3; del 4q35.2          del 4q35 (KLKB1)                               \-                                \-
  del 4q35.1→q35.2      186,468,992 - 190,880,409   4,411,417                                                                                                                                                                                                                                                  
  dup 6q27              168,336,052 - 168,596,251   260,199                     VOUS                                                                                                                                                                                                                           
  62                    del 7q11.23                 72,569,012 - 72,685,658     116,646             Pathogenic   del 7q11.23 atypical (*FZD9* nml)            dup Yp11.32; dup Yq12           dup Yp11.32; dup Yq12           \-                                             \-                                del 7q11.23 atypical (*FKBP6*, *FZD9* and *TBL2* nml)
  del 7q11.23           73,082,174 - 74,267,872     1,185,698                                                                                                                                                                                                                                                  
  del 7q11.23           74,298,092 - 74,601,104     303,012                                                                                                                                                                                                                                                    
  dup Xp22.33           192,991 - 2,693,037         2,500,046                                                                                                                                                                                                                                                  
  dup Yp11.31→q11.23    0 - 28,800,000              28,800,000                                                                                                                                                                                                                                                 
  dup 7p14.3            33,134,410 - 33,193,210     58,805                      Benign                                                                                                                                                                                                                         
  del 13q31.3           94,422,000 - 94,480,000     58,000                                                                                                                                                                                                                                                     
  63                    dup 16q24.1→q24.3           85,817,324 - 90,148,796     4,331,472           Pathogenic   nml                                          del 16p13.3; dup 16q24.3        del 16p13.3; dup 16q24.3        inconclusive                                   nml                               \-
  dup 14q11.2           20,213,937 - 20,425,051     211,114                     Benign                                                                                                                                                                                                                         
  del 16p13.3           105,320 - 203,254           97,934                                                                                                                                                                                                                                                     
  dup 22q11.22          22,314,463 - 22,573,637     259,174                                                                                                                                                                                                                                                    
  del 16p13.3           227,406 - 828,466           601,060                     VOUS                                                                                                                                                                                                                           
  dup Xq22.2            103,173,049 - 103,303,968   130,919                                                                                                                                                                                                                                                    
  64                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  65                                                No change                                                    nml                                          inconclusive                    nml                             \-                                             \-                                \-
  66                    dup 10q11.22                47,084,916 - 47,741,321     656,405             Benign       inconclusive                                 inconclusive                    nml                             \-                                             \-                                \-
  67                    del 8p21.3→p21.2            23,148,930 - 23,310,904     161,974             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  68                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  69                    dup 10q11.21                45,212,898 - 45,359,483     146,585             Benign       nml                                          del 16p13.3                     del 19p13.3                     \-                                             \-                                \-
  70                    del Xp11.23                 47,871,775 - 47,985,557     113,782             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  71                    dup 9p13.1→p12              40,294,324 - 42,374,011     2,079,687           Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  72                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  73                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  74                    dup Xq28                    152,667,088 - 153,903,395   1,236,307           Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-
  75                                                No change                                                    nml                                          nml                             nml                             nml                                            nml                               \-
  76                    dup Yq11.23                 27,266,362 - 28,693,558     1,427,196           VOUS         nml                                          nml                             nml                             \-                                             \-                                \-
  77                                                No change                                                    nml                                          nml                             nml                             nml                                            nml                               \-
  78                                                No change                                                    nml                                          nml                             nml                             nml                                            nml                               \-
  79                    del 2p11.2                  90,027,810 - 90,247,720     219,910             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  dup 21q11.2           14,687,571 - 15,214,708     527,137                                                                                                                                                                                                                                                    
  del Xp21.3            27,151,611 - 27,337,941     186,330                                                                                                                                                                                                                                                    
  80                    dup 2q13                    110,863,908 - 110,982,530   118,622             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  81                    dup 7q21.3                  95,467,621 - 96,178,713     711,092             Benign       nml                                          nml                             nml                             nml                                            nml                               \-
  del 9p23→p22.3        13,468,616 - 14,566,406     1,097,790                                                                                                                                                                                                                                                  
  dup 22q11.23→q12.1    25,732,697 - 25,910,879     178,182                                                                                                                                                                                                                                                    
  82                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  83                    del 8p23.1                  6,982,980 - 12,483,094      5,500,114           Pathogenic   nml                                          nml                             nml                             del 8p23 typical                               nml                               \-
  dup 2q22.3→q23.1      148,649,175 - 148,956,584   307,409                     Benign                                                                                                                                                                                                                         
  dup 5p13.2            36,902,936 - 37,159,877     256,941                                                                                                                                                                                                                                                    
  dup 6p21.1            44,810,418 - 45,334,537     524,119                                                                                                                                                                                                                                                    
  dup 8q22.2            100,111,153 - 100,528,645   417,492                                                                                                                                                                                                                                                    
  dup 11p15.2           14,504,463 - 14,906,450     401,987                                                                                                                                                                                                                                                    
  dup 13q31.3           92,492,127 - 92,815,210     323,083                                                                                                                                                                                                                                                    
  dup 17q11.2           29,574,712 - 29,699,649     124,937                                                                                                                                                                                                                                                    
  84                    dup 7q11.1→q11.21           61,074,194 - 62,403,985     1,329,791           Benign       nml                                          nml                             nml                             nml                                            nml                               \-
  dup 12p11.1           34,362,752 - 34,853,011     490,259                                                                                                                                                                                                                                                    
  dup 17q11.2           29,444,844 - 29,562,294     117,450                                                                                                                                                                                                                                                    
  dup 17q11.2           29,574,712 - 29,699,649     124,937                                                                                                                                                                                                                                                    
  85                    del 13q12.12                23,548,470 - 24,960,000     1,411,530           Pathogenic   del 22q11 typical                            nml                             nml                             del 22q11 typical                              inconclusive                      \-
  del 22q11.21          18,886,915 - 21,463,730     2,576,815                                                                                                                                                                                                                                                  
  dup 17q21.31          44,246,211 - 44,580,136     333,925                     Benign                                                                                                                                                                                                                         
  86                    del 22q11.21                18,889,490 - 20,312,668     1,423,178           Pathogenic   del 22q11 atypical                           nml                             nml                             del 22q11 atypical                             del 22q11 atypical                \-
                        dup 1p21.1                  103,155,605 - 103,510,258   354,653             Benign                                                                                                                                                                                                     
                        dup 5p13.2                  36,816,661 - 37,158,123     341,462                                                                                                                                                                                                                        
                        dup 17q11.2                 29,479,196 - 29,697,251     218,055                                                                                                                                                                                                                        
  87                    del 22q11.21                18,886,915 - 20,312,668     1,425,753           Pathogenic   del 22q11 atypical                           nml                             nml                             del 22q11 atypical                             del 22q11 atypical                \-
                        del 15q11.2                 24,357,212 - 24,472,002     114,790             Benign                                                                                                                                                                                                     
                        del 16p12.2                 21,578,388 - 21,839,340     260,952                                                                                                                                                                                                                        
  88                    dup 7p22.3→p21.1            44,935 - 19,155,339         19,110,404          Pathogenic   dup 7p typical                               dup 7p22.3                      dup 7p22.3                      \-                                             \-                                \-
  dup 7p21.1→p15.2      19,159,422 - 26,403,574     7,244,152                                                                                                                                                                                                                                                  
  dup 2q24.3            166,821,406 - 166,939,893   118,487                     Benign                                                                                                                                                                                                                         
  dup 5p13.2            36,877,640 - 37,158,123     280,483                                                                                                                                                                                                                                                    
  dup 9p24.1            5,112,844 - 5,252,074       139,230                                                                                                                                                                                                                                                    
  dup 22q11.21          18,886,915 - 19,008,108     121,193                                                                                                                                                                                                                                                    
  89                    dup 7q21.3                  95,467,621 - 96,178,713     711,092             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  del 9p23→p22.3        13,468,616 - 14,566,406     1,097,790                                                                                                                                                                                                                                                  
  90                    del 9p24.1                  8,012,608 - 8,227,101       214,493             Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  del Xq25              126,923,848 - 127,145,037   221,189                                                                                                                                                                                                                                                    
  dup Xp22.33           1,921,638 - 2,065,015       143,377                                                                                                                                                                                                                                                    
  91                    del 9p23→p22.3              13,466,329 - 14,566,406     1,100,077           Benign       nml                                          nml                             nml                             \-                                             \-                                \-
  dup 22q11.23→q12.1    25,650,648 - 25,910,879     260,231                                                                                                                                                                                                                                                    
  92                                                No change                                                    nml                                          nml                             nml                             \-                                             \-                                \-
  93                    del 5q14.3→q15              90,124,906 - 94,954,205     4,829,299           Pathogenic   nml                                          nml                             nml                             \-                                             \-                                \-

Abbreviations: Nml, normal; dup, duplication; del, deletion; VOUS, variant of uncertain clinical significance; pb, base pairs.
